Sun Pharma Q4 FY25 Results: PAT falls 19%, disappoints analysts; 550% dividend declared


Sun Pharma Q4 FY25 Earnings: Sun Pharma, a Mumbai-headquartered pharmaceutical giant, on Thursday reported a consolidated net profit of Rs 2,154 crore for the quarter ended March 31, missing analysts’ estimates. The quarterly net profit fell 19 per cent compared with the corresponding period a year ago, according to a regulatory filing. 

The drug maker’s March-quarter revenue grew 8.1 per cent on a year-on-year basis to Rs 12,959 crore, according to the filing.    

According to Zee Business research, Sun Pharma was estimated to register a net profit of Rs 2,795 crore with revenue of Rs 13,350 crore for the final three months of FY25. 

Sun Pharma Q4 FY25 Results | How the Mumbai-based pharma firm fared operationally

Sun Pharma’s margin improved to 28.68 per cent for the quarter ended March 31, 2025, from 25.32 per cent a year ago.

Margin is a key measure of a company’s profitability. 

Sun Pharma Q4 Earnings | How the Mumbai-based pharma firm fared operationally

Sun Pharma’s margin improved to 28.68 per cent for the quarter ended March 31, 2025, from 25.32 per cent a year ago.

Dividend per share

The pharma firm declared a dividend of Rs 5.5 per share to shareholders—a 550 per cent payout given the face value of Re 1 per equity share. 



Source link

Author Profile
Managing Director at Bitlance Tech Hub | 09158211119 | [email protected] | Web

Anurag Dhole is a seasoned journalist and content writer with a passion for delivering timely, accurate, and engaging stories. With over 8 years of experience in digital media, she covers a wide range of topics—from breaking news and politics to business insights and cultural trends. Jane's writing style blends clarity with depth, aiming to inform and inspire readers in a fast-paced media landscape. When she’s not chasing stories, she’s likely reading investigative features or exploring local cafés for her next writing spot.

Leave a Reply

Your email address will not be published. Required fields are marked *